retatrutide phase 2 nejm 2023 weight loss percent 48 weeks Retatrutide (not yet approved in US but people using anyway) promises even potentially greater weight loss amongst the GLP1 drugs. https://www.nejm .org/doi/full/10.1056/NEJMoa2301972 Retatrutide study sees significant weight

Healthcare policy discussions continue regarding potential modification of statutory insurance restrictions to include evidence-based obesity pharmacotherapy

Consult with the treating healthcare provider regarding any patient-specific contraindications

"You have nothing to lose (except maybe some extra pounds) and everything to gain in terms of wellness and confidence," said Bikman

An NP with a Master's degree in nursing and national board certification can independently prescribe GLP-1 medications in many states, while PAs typically require physician collaboration or supervision depending on state regulations

Abstract Inositols are sugar-like compounds that are widely distributed in nature and are a part of membrane molecules, participating as second messengers in several cell-signaling processes